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Abstract 9 
A straightforward single-step extraction method based on matrix solid-phase 10 
dispersion (MSPD), followed by  high-performance liquid chromatography with 11 
hybrid quadrupole time of flight mass spectrometry (LC-QTOF-MS), was 12 
developed and optimized to determine five non-steroidal anti-inflammatory drugs 13 
(Valdecoxib, Etoricoxib, Parecoxib, Celecoxib and 2,5-Dimethylcelecoxib) in 14 
sewage sludge samples. The influence of different operational parameters on the 15 
extraction efficiency a well as in the matrix effects of the produced extracts was 16 
evaluated in detail. Under final working conditions, freeze dried samples (0.2 g) 17 
were first soaked with 100 µL of aqueous potassium hydroxide solution (60%, 18 
w/v), mixed with 1 g of anhydrous sodium sulfate and dispersed with 1 g of Florisil. 19 
This blend was transferred to the top of a polypropylene column cartridge 20 
containing 3 g of silica. Analytes were recovered using 15 mL of hexane/acetone 21 
(1:2, v/v) mixture. The extracts were concentrated by evaporation and 22 
reconstituted with 1mL of methanol/water (1:1, v/v), filtered and injected in the LC 23 
system. Quantification limits from 0.005 and 0.05 ng g-1 and absolute recoveries 24 
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between 86 and 105% were achieved. Results indicated the presence of two of 25 
the targeted COXIBs in real samples of sewage sludge, the highest average 26 
concentration (22 ng g-1) corresponding to celecoxib. Moreover, the screening 27 
capabilities of the LC-QTOF-MS system demonstrated that the developed MSPD 28 
extraction procedure might be useful for the selective extraction of some other 29 
pharmaceuticals (e.g. amiodarone and their metabolite N-desethylamiodarone, 30 
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1. Introduction 38 
Active pharmaceutical ingredients (APIs) are a very large and diverse group of 39 
compounds used in considerable quantities through the world designed to 40 
prevent, cure and treat diseases and improve health. Non-steroidal anti-41 
inflammatory drugs (NSAIDs) are one of the most consumed groups [1,2]. As with 42 
many other API residues and metabolites, one of the most important routes into 43 
the environment is sewage treatment plants (STPs) and some studies have 44 
reported the occurrence of NSAIDs in treated wastewater effluents, indicating 45 
that some of these compounds are not efficiently removed in STPs [3,4,5]. On 46 
the other hand, when STPs appear efficient in removing pharmaceutical residues 47 
as judged by the absence in treated aqueous effluents, these residues frequently 48 
may remain intact accumulated in sludge. In contrast to the many studies of 49 
pharmaceutical residues in the aquatic environment, the occurrence and fate of 50 
pharmaceuticals in solid matrices, such as sludge, soil and sediments have been 51 
rarely studied [6], possibly because the matrix complexity, especially in the case 52 
of sludge. This means that several NSAIDs drugs (including the COXIBs), 53 
especially the more hydrophobic, low biodegradable compounds are likely re-54 
entering into the environment through the sludge [6,7]. 55 
The amount of sewage sludge produced per year in the UE is estimated over 10 56 
million tones [8, 9]. In particular, Spain produces around 1.13 million tons per year 57 
and, 81% are employed in agriculture, 7% are eliminated in landfill, another 7% 58 
is incinerated and 5% of tons go to other uses [10]. Consequently, it is a real 59 
technological challenge the elimination of these compounds as well as the 60 
analytical control of its levels in these complex matrices.  61 
Pharmaceutical residues in soils, sediments and sludge have been extracted by 62 
ultrasonic solvent extraction (USE) [4], microwave assisted extraction (MAE) [11] 63 
and pressurized liquid extraction (PLE, ASE) [4,12-14]. In most cases, the 64 
extracts need further clean-up using solid phase extraction (SPE) and 65 
concentration to provide analytical extracts allowing the reliable quantification of 66 
analytes.   An alternative strategy for the extraction of organic environmental 67 
pollutants is matrix solid-phase extraction (MSPD), developed by Baker et al.  [15] 68 
that has been applied for the extraction of a large variety of analytes from solid, 69 
semi-solid, viscous and biological matrices [16]. This technique involves a 70 
process allowing simultaneous extraction and clean-up of analytes from solid or 71 
semi-solid samples with significant reduction in solvent consumption not requiring 72 
particularly expensive instrumentation [6]. 73 
In this study, five COXIBs were selected on the basis of their recent use as a 74 
convenient alternative to the traditional non-steroidal anti-inflammatory drugs (t-75 
NSAIDs) [17]. The aim was to assess the suitability of the matrix solid-phase 76 
dispersion technique (MSPD) for the one-step extraction of COXIBs from sludge 77 
samples. While the necessary selectivity in the determination is provided by LC-78 
ESI-Q/TOF, the objective was to develop a simple process allowing the 79 
quantitative extraction of the analytes while providing clean extracts with a 80 
minimum of sample preparation operations. As far as we know this is the first time 81 
MSPD has been applied to process sludge samples for the analysis of COXIBs. 82 
Different important parameters, such as solid sorbent types, eluting solvents or 83 
the amount of additives were studied and optimized. The complete procedure 84 
was evaluated for linearity, sensitivity, matrix effects, repeatability and 85 
reproducibility demonstrating satisfactory performance.  Additionally, using the 86 
information gathered by the LC-QTOF-MS instrument, other non-target 87 
pharmaceutical residues were screened in the LC–MS chromatograms of 88 
samples which extends the practical applicability of the developed sample 89 
preparation procedure. 90 
2. Experimental 91 
2.1. Reagents, standards and materials 92 
Acetonitrile (ACN), methanol (MeOH) (gradient-grade, Lichrosolv), n-hexane, 93 
acetone, ethyl acetate (EtOAc) and dichloromethane (DCM) (Suprasolv) were 94 
purchase from Merck (Darmstadt, Germany). Ultrapure water was produced by 95 
means of a Milli-Q gradient A-10 system (Millipore, Billerica, MA, USA). The 96 
commercial selective COXIBs standards (Valdecoxib (VDC) (4-(5-methyl-3-97 
phenyl-4-isoxazolyl)benzenesulfonamide), Parecoxib (PRC) (N-{[4-(5-Methyl-3-98 
phenyl-1,2-oxazol-4-yl)phenyl]sulfonyl}propanamide), Etoricoxib (ETC) (5-99 
Chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine), Celecoxib (CLC) 100 
(4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide) 101 
and 2,5-Dimethylcelecoxib (2,5-DMCLC) (4-[5-(2,5-dimethylphenyl)-3-102 
(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide)),Amiodarone ((2-butyl-1-103 
benzofuran-3-yl)(4-{[2-(diethylamino)ethyl]oxy}-3,5-diiodophenyl)methanone) 104 
and  N-desethylamiodarone ((2-Butyl-1-benzofuran-3-yl){4-[2-105 
(ethylamino)ethoxy]-3,5-diiodophenyl}methanone), clotrimazole (1-[(2-106 
Chlorophenyl)(diphenyl)methyl]-1H-imidazole), micomazole nitrate salt (1-{2-107 
[(2,4-Dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole nitrate (1:1) 108 
) and ketoprofen (2-(3-Benzoylphenyl) propanoic acid) standards were obtained 109 
from Sigma-Aldrich (Madrid, Spain).  Potassium hydroxide (Pellets, 85%+, AC) 110 
was also purchased to Sigma-Aldrich, and sodium sulfate anhydrous was 111 
obtained from Panreac (Barcelona, Spain). Florisil (60-100 mesh) and silica 112 
bonded to ethylenediamine-N-propyl groups (PSA sorbent) were purchased from 113 
Supelco (Bellefonte, PA, USA). Diatomaceous earth was provided by Sigma-114 
Aldrich and silica bonded to C18 (C18 sorbent) was purchased to Agilent 115 
Technologies (Santa Clara, CA, USA). Silica gel 60 (0.040-0.063 mm) was 116 
obtained from Merck. For some experiments, Florisil and silica gel were activated 117 
at 120 ºC for at least 12 h and then allowed to cool at room temperature in a 118 
desiccator before use. 119 
MSPD empty polypropylene syringes (15 mL capacity) and 20 µm polyethylene 120 
frits were acquired from International Sorbent Technology (Mid Glamorgan, UK). 121 
2.2. Samples and sample preparation 122 
Stabilized and non-stabilized, spiked and non-spiked, sewage sludge samples 123 
were used in this study. The sludge samples were obtained from two STPs 124 
located in the Northwest of Spain. 125 
MSPD conditions were optimized with a pool of non-stabilized sludge fortified with 126 
the target analytes at 500 ng g-1 level. Spiked samples were prepared by mixing 127 
an accurately weighed amount of sludge with a standard solution of COXIBs in 128 
acetone. The slurry was manually blended and left in the hood for 2 days 129 
(protected from direct exposure to sun light) to allow acetone removal. This 130 
operation was carried out one month before sample analysis. Spiked and non-131 
spiked sewage sludge samples were freeze dried and stored in amber glass 132 
bottles at 4ºC. Recoveries of the extraction procedure were evaluated with a pool 133 
of primary sludge samples, spiked at different concentration levels (100, 250 and 134 
500 ng g-1). Other sludge samples of different origin, spiked at the lower 135 
concentration level (100 ng g-1) were used to verify the absence of matrix effects.  136 
The influence of different operational parameters of the MSPD method such as 137 
the type of dispersant and amount/type of additives, clean-up co-sorbents and 138 
extractant solvent were systematically tested considering extraction efficiencies 139 
and matrix effects. Under final working conditions, freeze dried sludge samples 140 
(0.2 g) were first soaked with 100 µL of aqueous potassium hydroxide solution 141 
(60%, w/v) and mixed with 1 g of anhydrous sodium sulfate in a glass mortar with 142 
a pestle. Then, 1 g of Florisil was added and the mixture was blended and 143 
dispersed during 3 min. The dispersed sample was transferred into a 144 
polypropylene column fitted with a single bottom frit containing a layer of 3 g of 145 
silica as clean-up sorbent, and the whole solid phase is covered with another 20-146 
µm frit. Analytes were recovered passing 15 mL of hexane/acetone (1:2, v/v) 147 
mixture through the packed cartridge. The extracts were concentrated by 148 
evaporation under a stream of nitrogen (e.g. using a Turbo Vap), and finally 149 
reconstituted with 500 µL of MeOH diluting to 1 mL with ultrapure water. Extracts 150 
were filtered through 0.2 µm GHP Acrodisc 13 mm syringe filters and 15 µL were 151 
injected into the LC-QTOF-MS system. 152 
2.3. Chromatographic separation and determination 153 
Compounds were determined using an Agilent LC-ESI-QTOF-MS system 154 
(Wilmington, DE, USA). The LC instrument was a 1200 Series consisting of a 155 
vacuum degasser unit, a binary high pressure gradient pump, a chromatographic 156 
oven and an auto sampler. The Q-TOF mass spectrometer was a 6520 model, 157 
equipped with a Dual-Spray ESI source and a hexapole collision cell controlled 158 
by the Mass Hunter software (version B.05.01). Compounds were separated in 159 
an Ascentis Express C8 fused core column (Supelco) of 50 mm×2.1 mm and 2.7 160 
μm particle size. The mobile phase consisted of ultrapure water containing 0.1% 161 
acetic acid (eluent A) and MeOH/ACN (80:20, v/v) (eluent B). Elution conditions 162 
were taken from a previous study [5]. In short, the gradient started with 10% 163 
solvent B, which was maintained for 2 min and then increased to 80% solvent B 164 
over 5 min, and then hold for 5 min. The gradient decreased back to the initial 165 
conditions (10% solvent B) in 5 min and 13 min of column re-equilibration was 166 
allowed. Flow rate was set at 0.2 mL min-1 and the oven temperature was 167 
maintained at 40ºC. Injection volume was 15 μL. 168 
 169 
2.4. Matrix effects, MSPD extraction efficiency and samples quantification  170 
Potential matrix effects (ME) occurring in the ESI source and MSPD extraction 171 
efficiency were studied. In our work, the quantitative evaluation of matrix effects 172 
follows the strategy suggested by Matuszewski et al. [18]. Matrix effects during 173 
ESI were tested for each analyte spiking an aliquot of the final MSPD extract 174 
using a non-spiked aliquot from each sample as contrast. So, the difference in 175 
responses (peak area) of the spiked (Rse) and non-spiked (Rnse) extracts, was 176 
compared to the response of a standard solution prepared in MeOH/H2O (1:1, 177 
v/v) (Rs) containing the adopted spiking concentration of the analyte. Matrix 178 
effects percentage was calculated as: %ME= [(Rse-Rnse)/Rs] × 100. Thus, a ME 179 
value of 100% indicates the absence of significant effects in the ionization yields 180 
both for standard solutions and sludge samples extracts. 181 
The efficiency of the MSPD extraction was evaluated as the ratio between the 182 
concentration measured in the extract from the spiked sample and the 183 
concentration added to the sample, multiplied by a factor of 100. 184 
The overall recoveries (R) of the procedure were calculated as follows: %R= [(Cs-185 
Cb)/Ct] × 100, where Cs is the concentration measured in the extract from the 186 
spiked sample, Cb is the concentration in the extract from the non-spiked fraction 187 
of the same sample and Ct is the concentration added to the sample. Cs and Cb 188 
were determined using calibration curves obtained from standard solutions 189 
prepared in MeOH/H2O (1:1, v/v).  190 
3. Results and discussion 191 
3.1 Preliminary experiments and MSPD extraction optimization. 192 
Several preliminary extraction assays were conducted in order to explore the 193 
main parameters affecting MSPD process, such as the type of sorbent and the 194 
solvent polarity, as well as the clean-up sorbents and the sample additives. These 195 
experiments were conducted using multilevel factorial experimental designs as 196 
well as some one factor at a time trials to fix the levels of some of the factors 197 
considered. An important aspect to consider in the optimization of the conditions 198 
for MSPD is the intentional ionization or suppression of ionization of analytes and 199 
matrix components. This operation can be carried out by adding acids, bases, 200 
salts, antioxidants, etc., during sample blending and/or as additives to the eluting 201 
solvents. Starting conditions in these preliminary experiments were taken from 202 
published reports [19, 20] dealing with MSPD extraction of hydrophobic 203 
compounds from sludge samples. These reports clearly show the convenience 204 
of soaking the freeze dried samples with KOH before proceeding with the 205 
dispersing stage. The concentration of KOH as well as the use of methanolic or 206 
aqueous solutions of KOH was investigated. Also a drying step with anhydrous 207 
sodium sulfate (0.5 g) was introduced before the dispersion. This action is 208 
necessary to help the sorbent dispersants (e.g. activated Florisil and PSA), 209 
extracting the hydrophobic fraction of samples. Considering the detection limits 210 
of the QTOF-MS detector a fixed amount of 0.2 g of sludge sample was fixed in 211 
all experiments. Additionally, were evaluated factors such as the nature and 212 
proportions of the solvent mixtures (hexane/acetone (1:1 and 1:2 v/v), AcOEt,  213 
ACN/AcOEt (1:1, and 2:1, v/v),  DCM/MeOH (90:10, v/v), ACN/acetone (1:1 and 214 
2:1, v/v)) used to elute analytes from cartridges, as well as the needed volumes 215 
to fully recover the analytes. A very important parameter in MSPD is the use of 216 
clean-up layers in the cartridges helping in obtaining extracts amenable to 217 
chromatographic separations. Florisil, silica, PSA and C18 in different amounts 218 
and combinations were considered in these preliminary experiments.  219 
Except for etoricoxib, the extraction efficiencies obtained with Florisil as 220 
dispersant were higher than those obtained with PSA. Some other sorbents (silica 221 
and diatomaceous earth) were assayed as dispersants but produced worse 222 
extraction efficiencies than Florisil. 223 
The analysis of experimental design results (not shown) indicated that the 224 
proportions of silica and Florisil used in the clean-up layer were the most 225 
significant factor for the majority of analytes. Best extractions efficiencies 226 
(between 42 and 118%) were obtained with the combination of Florisil as 227 
dispersant and 1 g of Florisil and 2 g of silica as clean-up layers. Also the amount 228 
of KOH played a significant effect for some analytes (e.g. negative for VDC) as 229 
well as the nature of the solvent used to elute the cartridges. The mixture 230 
DCM/MeOH (90:10, v/v) produced visually dirty extracts that were not injected. 231 
Mixtures containing ACN played a clear negative effect in the extraction of ETC, 232 
but positive for CLC and 2,5DMCLC). The mixtures hexane/acetone (1:1 and 1:2) 233 
appears providing a compromise solution for most analytes, with extraction 234 
efficiencies between 90 and 119%, when KOH was used in aqueous solution 235 
because the interaction of the nature of the solvent mixtures and the solvent of 236 
KOH appear as significant. Thus, mixtures hexane/ acetone were retained for 237 
further experiments.   238 
The effects of different additives (no additive, water, KOH(MeOH) (35%, w/v), 239 
KOH(aqueous)(120%, w/v)) in the efficiency of the MSPD extraction were compared.  240 
Fig. 1 shows that 0.1 mL KOH(aqueous) (120%, w/v) provided the higher extraction 241 
efficiencies (between 90%  and 106%).  Therefore, subsequent experiments were 242 
performed using KOH(aqueous) (120% w/v) and  several mixtures of silica and 243 
Florisil  (3 g of total amount) as the clean-up layer were developed.  From the 244 
results obtained (Fig. 2) it is apparent, especially for PRC, that the efficiencies of 245 
the MSPD extraction were better using a single co-column formed by 3 g of silica. 246 
The influence of the amount of sodium sulfate during the drying step on the 247 
efficiency of the MSPD extraction was also evaluated (Fig. 3).  For the majority 248 
of analytes, recoveries increased when the amount of sulfate increases from 0.5 249 
to 1 g (which corresponds to [g sulfate / mL KOH(aqueous)] ratios from 5 to 10), but 250 
decreases when the amount of sulfate increases from 1 to 2 g (ratios from 10 to 251 
20). 252 
Another stage in the optimization of the MSPD procedure consisted on the 253 
evaluation of the effect of the amount of aqueous KOH added during the initial 254 
blending of samples. Preliminary assays indicated that this treatment was 255 
statistically significant to maximize COXIB’s recoveries and also that this factor 256 
and the composition of the solvent mixture used to elute the analytes are not 257 
independent. Thus, a series of experiments were carried out varying the amounts 258 
of added alkali, using hexane/acetone (1:1 and 1:2, v/v) as extraction solvents.  259 
When using hexane/acetone 1:1, only the efficiency for PRC extraction was 260 
slightly increased (about 10%) on increasing the percentage of KOH, but 261 
extraction efficiencies were on average 36–63% lower for all analytes (results not 262 
shown) when larger (c.a. 200  µL) amounts 120%, w/v aqueous KOH are added. 263 
Using hexane/acetone (1:2, v/v) as solvent, the higher efficiencies of extraction 264 
were obtained with 100 µL of 60% aqueous KOH (Figure 4), being similar in value 265 
to those obtained with 100 µL of 120 % aqueous KOH using hexane/acetone (1:1, 266 
v/v). Thus, similar extraction efficiencies can be obtained by adjusting the relative 267 
composition of the sample soaking agent and the final eluting solvents mixture. 268 
However, as the Figure 4 shows, the elution profiles produced by hexane/acetone 269 
mixtures are also dependent of the amount of aqueous KOH used in the soaking 270 
stage. Figure 4 displays the elution profiles of the target compounds from the 271 
MSPD packed syringe, using 10 mL fractions of hexane/acetone 1:2 v/v. It is clear 272 
in that figure that not only the recoveries for the analytes are better when using 273 
60% aqueous KOH. If lower percentages of KOH are used, only the first fraction 274 
contains the analytes which cannot be detected in further fractions. A quite similar 275 
behavior is apparent for higher concentrations of KOH (120%) although in that 276 
case, small amounts of analytes are also detected in the second and third 277 
fractions. If 60% KOH is used, all analytes are eluted over 80% in the first fraction 278 
and elution is nearly quantitative in the second fraction.  Some additional 279 
experiments demonstrated that 15 mL of mixture hexane/acetone (1:2, v/v) were 280 
sufficient to elute the analytes from the MSPD column. In all, conditions described 281 
in section 2.2 were adopted as optimal for a fixed amount of 0.2 g of freeze dried 282 
sludge sample. These conditions provide a really simple and relatively quick 283 
procedure for sample preparation of sludge in the analysis of COXIBs residues.   284 
 285 
3.2. Performance of the method 286 
Table 1 summarizes some features of the optimized method, including 287 
chromatographic and MS determination parameters.  288 
Nine-point calibration curves were constructed using linear regression analysis 289 
by injecting standard solutions in the range of 0.005-200 ng mL-1.  Recoveries of 290 
the overall sample preparation process were calculated against external 291 
standards.. Recoveries during the procedure optimization process were 292 
evaluated with a pool of primary sludge spiked at different concentration levels 293 
(Table 1). Later, verified with some stabilized and non-stabilized sludge samples 294 
of different origins and sampling dates, spiked with target compounds at 100 ng 295 
g-1 (Table 2). Recoveries ranged from 86 to 105%, with standard deviations below 296 
4%.   Most recovery data shown in Tables 1 and 2 correspond to repeatability 297 
conditions (n=3, same day). Data for samples fortified at 250 ng g-1 correspond 298 
to extractions performed in three consecutive days (9 replicates).   ME values 299 
ranging from 91 to 105 % (Table 1) indicates the absence of significant changes 300 
between ionization yields for standard solutions and sludge extracts, thus 301 
confirming that the developed extraction procedure provides quite clean extracts 302 
which avoids the need of time consuming standard additions calibration. 303 
Instrumental limits of quantification (LOQs) were calculated using signal to noise 304 
ratio (S/N) as 10×S/N.  Procedural blanks did not exhibit detectable traces of 305 
COXIBs, thus the attained LOQs were controlled by sensitivity of the LC-QTOF-306 
MS. Consequently, LOQs of the reported method were calculated from 307 
instrumental LOQs multiplied by the final extract volume (1 mL) and divided by 308 
the sample intake (0.2 g).  The attained LOQs (referred to freeze dried sludge 309 
material) ranged from 0.005 (for ETC) to 0.05 ng g-1 (for VDC, CLC and 2,5-310 
DMCLC) . 311 
 312 
3.3 Sludge sample analysis 313 
The optimized method was applied to determine COXIBs in several samples of 314 
non-stabilized and stabilized sludge, collected during different months between 315 
November 2014 and December 2015 from two STPs serving cities of about 316 
100000 inhabitants. ETC was detected in all samples, with average 317 
concentrations ranging to 1.8 to 14.7 ng g-1 (Table 2). CLC could be detected in 318 
three samples (collected on 2015), with average concentrations ranging to 6.5 to 319 
21.6 ng g-1 (Table 2). Although it is clear that results obtained for sludge samples 320 
are insufficient to evaluate the efficiency of STPs, the comparison of 321 
concentrations found in  non-stabilized and stabilized sludge samples (samples 322 
collected in November 2014 and December 2015, Table 2), and particularly   the 323 
presence of some investigated COXIBs in stabilized sludges, suggest low 324 
efficacy of the waste water treatments done. Fig. 5 shows the extracted LC-MS 325 
chromatogram for a non-stabilized sludge. The overall score for the peaks was 326 
between 95.6 and 99.7 over 100, and the mass error remained below 1 ppm, as 327 
shown in the figure (Fig 5 A).  The accurate ion products scan MS/MS spectrum 328 
of the peaks of each investigated compound in the samples provided an 329 
unambiguous confirmation of its identity. Absolute differences between 330 
calculated and experimental masses of the most intense ion in MS/MS spectra 331 
were between 2.5 to 1.4 ppm (Fig. 5 B).  It should be pointed out that stabilized 332 
sludge is used frequently as fertilizer in agriculture, and these practices may 333 
contribute to the potential bioaccumulation in terrestrial organisms, and/or to the 334 
transferring of the target compounds to the water cycle and eventually into the 335 
food chain. 336 
 337 
3.4 Applicability of the method to the Screening of other pharmaceuticals in 338 
sludge. 339 
The information existing in LC-MS files of the analyzed sludge samples was used 340 
to investigate the presence of other non-target pharmaceutical residues. The 341 
mechanisms that control pharmaceuticals sorption onto sludge are complex not 342 
depending only on the lipophilicity of the compounds. Other factors, including 343 
solubility, vapor pressure, and the environmental conditions (temperature, air 344 
disturbance, or soil organic-matter content), are also important [21]. To develop 345 
a post-target screening in the processed sludge samples some frequently 346 
reported [22, 23] pharmaceuticals with relatively high values of log KOW were 347 
considered (Table S1). 348 
The approach used in post-target studies has been described in several articles 349 
[24, 25]. In short, the Mass Hunter software was used to search for their 350 
characteristic ions (normally [M-H]+) in the LC-MS chromatograms of samples, 351 
within a mass window of 20 ppm around their theoretical values. This software 352 
extracts the accurate LC-MS chromatograms and compares the experimental MS 353 
spectra of detected peaks with the theoretical (calculated) ones. Then, a 354 
normalized score (0-100), which combines mass accuracy, isotopic pattern and 355 
spacing among ions in the cluster for the characteristic ion, is calculated. A score 356 
of 100 represents a perfect match between the empirical and the theoretical 357 
spectrum. Tentative identifications obtained from this post-target strategy 358 
requires additional confirmation, using product ion scan MS/MS spectra (a 359 
second injection was made considering different collision energies). 360 
Two anti-mycotic drugs, miconazole and clotrimazole were detected in all the 361 
samples studied. Amiodarone, a drug prescribed for the treatment of chronic and 362 
severe cardiac diseases and its N-desethyl metabolite were also detected in all 363 
samples except for a pool of samples collected on May 2015. Ketoprofen, an anti-364 
inflammatory drug (t-NSAIDs), was detected in five samples (both in stabilized 365 
and non-stabilized sludge) of the seven studied. 366 
Fig. 6 shows the LC–MS chromatogram for the characteristic ions of the 367 
ketoprofen (255.1009 Da, retention time 12.15 min) corresponding to the extract 368 
from a non-stabilized sludge sample and confirmation MS spectrum. Similar 369 
figures for Miconazole (414.9936 Da, retention time 12.71 min), Clotrimazole 370 
(277.0788 Da, retention time 12.10 min), amiodarone (646.0310 Da, retention 371 
time 13.21 min), and N-desethylamiodarone (617.9997 Da, retention time 13.10 372 
min), have been included in Figure S1 of the supplementary material. The 373 
superposed boxes represent the theoretical spectra of the peak. The calculated 374 
scores stayed between 91.34 and 98.49 over 100, and the mass error remained 375 
below 4 ppm (Fig S1 A). The MS/MS spectra for these ions displayed a 376 
fragmentation pattern coherent with de chemical structures of the above drugs 377 
(Fig. S1 B). Some of these findings (e.g. for amiodarone) have been reported 378 
previously [26]. Furthermore, the presence of the compounds in the samples was 379 
confirmed by spiking with pure standards verifying retention times coincidence.  380 
 381 
4 Conclusions 382 
This study has demonstrated for the first time the suitability of MSPD as a single-383 
step extraction method for the quantitative determination of the most relevant 384 
COXIB non-steroidal anti-inflammatory drugs in sewage sludge samples. The 385 
proposed method improved the selectivity of COXIBs extraction, providing clean 386 
extracts with no significant matrix effects during ESI ionization. The developed 387 
MSPD method followed by LC-QTOF-MS determination provided LOQs low 388 
enough for selective and unambiguous determination of target compounds in 389 
sludge samples. Data obtained for real samples confirmed the systematic 390 
presence of CLC and also a high frequency of ETC in sludge samples from urban 391 
STPs. Finally, the post-target capabilities of the QTOF instrument were used for 392 
the post-target identification of additional pharmaceuticals in the samples. These 393 
results show clearly that a simple MSPD extraction method could be extended to 394 
the extraction of several other drug residues (e.g. the basic drugs clotrimazole, 395 
miconazole, amiodarone and their metabolite N-desethylamiodarone, and acid 396 
drugs as ketoprofen) from complex sludge samples. 397 
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Figure legends 524 
 525 
Figure 1.  Efficiency of MSPD extraction as a function of the additive. (Sample: 526 
0.2  g ; Elution solvent: 30 mL hexane/acetone  (1:1, v/v)), n=3. 527 
 528 
Figure 2. Efficiency of MSPD extraction as a function of the co-column. (Sample: 529 
0.2  g ; Elution solvent: 30 mL hexane/acetone  (1:1, v/v)), n=3. 530 
 531 
Figure 3. Efficiency of MSPD extraction as a function of the amount of sodium 532 
sulfate added as drying agent. (Sample: 0.2 g; Elution solvent: 30 mL 533 
hexane/acetone (1:1, v/v); n=3) 534 
 535 
Figure 4. Influence of the amount of aqueous KOH on the efficiency of the MSPD 536 
extraction and elution profiles of COXIBs from MSPD cartridge using fractions 537 
(10 mL each) of hexane/acetone (1:2, v/v). (Volume of aqueous KOH:  100 µL in 538 
all experiments).  539 
 540 
Figure 5.  A) LC-QTOF-MS chromatograms (20 ppm mass extraction window) for 541 
the [M+H]+ ions for CLC and ETC, with their MS spectra, in a non-stabilized 542 
sludge sample. Boxes in red correspond to theoretical MS spectra for both 543 
species. B) Experimental MS/MS spectra for above compounds. 544 
 545 
Figure 6.  A) LC-MS chromatograms for ketoprofen [M+H]+ ion,  and B) MS/MS 546 
confirmation spectrum. 547 
Table 1 Summary of chromatographic and QTOF–MS determination parameters, linearity data, Global recoveries (R%, 











aUsed as quantification ion  
b Concentrations added to sludge samples 
c Intermediate precision conditions 



















b100 ng g-1 
(n=3) 
b,c250 ng g-1 
(n=9) 
b500 ng g-1 
(n=3) 




















































Table 2. Concentration (ng g-1, Mean±SD) of COXIBs in environmental sludge samples and recoveries (%, aAverage ±SD) of the optimized 
method, n=3 replicates  
a Concentrations added to sludge samples:100 ng g-1 




















































Date      May 2014       November 
2014 
     May 2015    December 
2015 
    November 
2014 
   December 
2015 
   November 
2014 
   December 
2015 
    November 
2014 
   December 
2015 
VDC n.d. n.d. n.d n.d. 86.4±2.0 102.1±1.4 n.d. n.d. 84.9±2.0 89.1±1.3 
ETC 5.4±0.6 14.7±0.5 1.9±0.2 11.4±0.5 100.6±1.6 103.2±1.0 14.1±0.5 1.8±0.1 
 
97.6±0.3 105.7±1.7 
PRC n.d. n.d. n.d. n.d. 85.7±1.7 105.3±1.6 n.d. n.d. 87.1±0.6 88.1±1.1 
CLC n.d. n.d. 21.6±1.6 12.5±0.9 94.8±1.6 96.2±2.3 n.d.   6.5±0.25 94.5±1.6 96.5±2.1 
      2,5-DMCLC n.d n.d n.d n.d 90.5±2. 87.1±2.0 n.d n.d 89.3±2.2 89.9±2.0 
Table S0 Studied COXIBs and physicochemical properties.  




















9.83±0.10 (Most acidic) 











5.08±0. 10 (Most acidic) 
 











9.68±0.10 (Most acidic) 












9.67±0.10 (Most acidic) 
-4.02±0.10 (Most Basic) 
 
3.120±0.696 
*Calculated using Advanced Chemistry Development (ACD/Labs) Software Solaris V 11.02 (©1994-2015), Chemical Abstracts 
Service (CAS), American Chemical Society, DC, 2015. 
 
 
Table S1.- Summary of pharmaceuticals included in the screening study 
 CAS number Formula [M+H]+ mass pKa logKOW Class 
Amiodarone 1951-25-3 C25H29I2NO3 646.0310 9.37 7.81 Antiarrhythmic 
 Amitryptiline 50-48-6 C20H23N 278.1909 9.18 4.41 Antidepressant 
 Atorvastatin 134523-00-5 
 
C33H35FN2O5 559.2603 0.38 ; 4.29 3.85 Antidepressant 
 Azelastine 58581-89-8 C22H24ClN3O 382.1681 9.16 3.47 Antiasthmatic 
 Azithromycin 83905-01-5 C38H72N2O12 749.5151 8.59;13.28 2.58 Antibiotic 
 Bromocriptine 25614-03-3 C32H40BrN5O5 654.2286 6.44; 9.60 
 
8.60 Antiparkinson 
 Carbamazepine 298-46-4 C15H12N2O 237.1022 13.94 2.67 Antiepileptic 
Analgesic 
Anticonvulsant 
Chlorpromazine 50-53-3 C17H19ClN2S 319.1030 9.41 5.20 Antipsychotics 
Chlorprothixene 113-59-7 C18H18ClNS 316.0921 9.05  5.21 Antipsychotic 
Climbazole 38083-17-9 C15H17ClN2O2 293.1051 5.66 3.50 Antimycotic 
Clomipramine 303-49-1 C19H23ClN2 315.1623 9.46 4.94 Antidepressants 
Clotrimazole 23593-75-1 C22 H17 Cl N2 277.0788 
[M-C3H3N2]+ 
6.12 4.10 Antimycotic 
Cimetidine 51481-61-9 C10H16N6S 253.1230 7.07;14.13 -0.07 Antiulcer 
 Ciprofloxacine 85721-33-1 C17H18FN3O3 332.1405 6.40 ; 8.70 1.60 Antibiotic 
Clemastine 15686-518 C21H26ClNO 344.1776 10.23 5.30 Dermatologic drug 
 Codeine 76-57-3 C18H21NO3 300.1594 8.23; 13.40 1.39 Antitussive 
 Cyproheptadine 129-03-3 C21H21N 288.1747 8.95 5.80 Dermatologic 
Dihydroergotamine 511-12-6 C33H37N5O5 584.2867 7.22 ;9.64 5.70 Analgesic 
 
Diphenhydramine 88637-37-0 C17H21NO 256.1696 8.76 3.00 Antiparkinson 
 Domperidone 57808-66-9 C22H24ClN5O2 426.1691 9.0; 11.11 4.05 Antiemetic 
 Doxepine 1668-19-5 C19H21NO 280.1696 9.40 3.84 Antidepressant 
 Doxycycline 564-25-0 C22H24N2O8 445.1605 4.50; 10.84  1.78 Antibiotic 
 Duloxetine 116539-59-4 C18H19NOS 298.1260 10.0 4.81 Antidepressant 
 Econazole 27220-47-9  
 





C24H21F2NO3 408.1397  9.72 3.96 Antilipidemic 
Flucomazole 86386-73-4   C13H12F2N6O 
 
307.1113 2.64;11.01 0.45 Antimycotic 
Escitalopram 128196-01-0 C20H21FN2O 325.1711 9.57 3.47 Antidepressant 
 Etaconazole 60207-93-4  
 
C14H15Cl2N3O2 328.0614 2.90 3.60 Antimycotic 
Fluoxetine 54910-89-3 C17H18F3NO 310.1413 10.05  3.93 Antidepressant 
 Fluphenazine 69-23-8 C22H26F3N3OS 438.1821 7.39; 14.96 3.92 Antipsychotic 
Haloperidol 52-86-8 C21H23ClFNO2 376.1474 8.04; 13.86 3.76 Antipsychotic 
Ketoconazole 65277-42-1  
 
C26H28Cl2N4O4 531.156 6.88 4.30 Antimycotic 
Ketoprofen 22071-15-4 C16H14O3 255.1009 4.23 2.91 Anti-inflammatory 
Levomepromazine 60-99-1 C19H24N2OS 329.1682 9.32 4.94 Analgesic; 
A ti h ti  
 
Lidocaine 137-58-6 C14H22N2O 235.1805 7.96 ;14.23 2.20 Local Anesthetic 
Meclizine 569-65-3 C25H27ClN2 391.1936 6.73 5.28 Antiemetic 
 Miconazole 22916-47-8  
 
C18H14Cl4N2O 414.9936 6.64 6.10 Antimycotic 
N-Desethylamiodorone 83409-32-9 C23H25I2NO3 617.9997 9.01 7.32 Metabolite 
Amiodarone 




9.13 4.88 Metabolite 
Sertraline 
 
Ofloxacine 82419-36-1 C18H20FN3O4 362.1511 5.19;7.37 1.85 Antibiotic 
Paroxetine 61869-08-7 C19H20FNO3 330.1500 9.68 3.70 Antidepressant 
Perphenazine 58-39-9 C21H26ClN3OS 404.1558 7.39;14.96 3.94 Antipsychotic 
Pizotifen 15574-96-6 C19H21NS 296.1467 9.04bp 2.71 Antidepressant 
Promethazine 60-87-7 C17H20N2S 285.1420 8.98bp 4.89 Antienemic 
Quinacrine 83-89-6 C23H30ClN3O 400.2150 10.47 5.59 Antimalarial, 
antiplatyhelmintic 
Roxithromycin 80214-83-1 C41H76N2O15 837.5318 8.16; 13 2.84 Antibiotic 
Sertraline 79617-96-2 C17H17Cl2N 306.0811 9.47 5.08 Antidepressant 
 Simvastatin 79902-63-9  
 
C 25H38O5 419.2792 13.49 4.72 Antilipemic 
Sulfamethoxazole 723-46-6 C10H11N3O3S 254.0594 1.39; 5.81 0.70 Antibiotic 
Sulfapyridine 144-83-2 C11H11N3O2S 250.0645 2.13;8.54 0.47 Antibiotic 
Tamoxifen 10540-29-1 C26H29NO 372.2322 8.69 5.13 Anti-estrogen 
Terbinafine 91161-71-6 C21H25N 292.206 7.1 5.60 Antimycotic 
Tetracycline 60-54-8 C22H24N2O8 445.1605 4.50; 11.02 0.62 Antibiotic 
Tramadol 27203-92-5 C16H25NO2 264.1958 9.61; 14.47 2.32 Analgesic 
Verapamil 52-53-9 C27H38N2O4 455.2904 8.97 4.02 Vasodilator agent 
Zolpidem 82626-48-0 C19H21N3O 308.1757 6.77 3.089 Sedative 
Figure 1.-Efficiency of MSPD extraction as a function of the  additive. 




























3 g silica  2 g silica +1 g Florisil  1 g silica +2 g Florisil
Figure 2.- Efficiency of MSPD extraction as a function of the co-column. Sample: 0.2  g 














0.5 g 1 g  2 g
Figure 3. Efficiency of MSPD extraction as a function of the  amount of sodium sulfate 
added as drying agent. Sample: 0.2  g .Elution solvent: 30 mL hexane/acetone (1:1, 
v/v),n=3
Figure 4. Influence of the amount of  aqueous KOH on  the efficiency of the MSPD extraction and  elution profiles 
of COXIBs from  MSPD  cartridge  using fractions (10 mL each) of  hexane/acetone (1:2, v/v). Volume of 
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+ EIC(359.0616) Scan_Sludge_samples_Etoricoxib_MS01.d  Smooth
Counts (%) vs. Acquisition Time (min)


























C18 H15 Cl N2 O2 S: + Scan (10.927-11.190 min, 17 Scans) Frag=160.0V Sludge_samples_Etoricoxib01.d  Subtract
359.0613
([C18 H15 Cl N2 O2 S]+H)+
Counts vs. Mass-to-Charge (m/z)
358 358.5 359 359.5 360 360.5 361 361.5 362 362.5 363 363.5 364 364.5 365 365.5 366 366.5 367
361.0580













+ EIC(382.0832) Scan_Sludge_samples_Celecoxib_MS01.d  Smooth
Counts (%) vs. Acquisition Time (min)


























C17 H14 F3 N3 O2 S: + Scan (12.914-13.023 min, 14 Scans) Mostras_Efectomatriz17.d  Subtract 
382.0836
([C17 H14 F3 N3 O2 S]+H)+
385.5189
Counts vs. Mass-to-Charge (m/z)
























Counts (%) vs. Mass-to-Charge (m/z)





































Counts (%) vs. Mass-to-Charge (m/z)

































Figure 5. A) LC-QTOF-MS chromatograms (20 ppm mass extraction window) for the 
[M+H]+ ions for CLC and ETC, with their MS spectra, in a non-stabilized sludge sample. 
Boxes in red correspond to theoretical MS spectra for both species. B)Experimental 



























Counts (%) vs. Mass-to-Charge (m/z)
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Score 95.67
[M-H]+ calculated 255.1016
















Counts (%) vs. Acquisition Time (min)
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Counts vs. Acquisition Time (min)
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Counts vs. Mass-to-Charge (m/z)
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11.8 12 12.2 12.4 12.6 12.8 13 13.2 13.4 13.6 13.8 14 14.2 14.4 14.6 14.8 15 15.2 15.4 15.6 15.8
























([C25 H29 I2 N O3]+H)+
647.0359
([C25 H29 I2 N O3]+H)+
Counts (%) vs. Mass-to-Charge (m/z)














Counts vs. Acquisition Time (min)
12.3 12.4 12.5 12.6 12.7 12.8 12.9 13 13.1 13.2 13.3 13.4 13.5 13.6 13.7 13.8 13.9 14 14.1 14.2 14.3 14.4 14.5 14.6 14.7 14.8
Blank procedural
Real sample
+ ESI Product Ion (13,099min) Frag=160.0V CID@20.0 (617.99969[z=1] -> **) 















([C23 H25 I2 N O3]+H)+
619.0032
([C23 H25 I2 N O3]+H)+
618.2013
620.0072
([C23 H25 I2 N O3]+H)+
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Counts (%) vs. Mass-to-Charge (m/z)
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Counts (%) vs. Mass-to-Charge (m/z)





























Error 2 ppm N-desethylamiodarone
Figure S1. A) LC-MS chromatograms ([M+H]+ ions) for miconazole, amiodarone
and N-desethylamiodarone, and [M-C3H3N2]+ for clotrimazole. B) MS/MS spectra
interpretation .
